罗沙司他与促红细胞生成素治疗维持性血液透析肾性贫血患者的效果比较  

Comparison of effects of Roxadustat and erythropoietin in treatment of renal anemia of patients undergoing maintenance hemodialysis

作　　者：王华英 张洁[2] WANG Huaying;ZHANG Jie(Department of Nephropathy and Rheumatology of the Second People’s Hospital of Xinxiang City,Xinxiang 453000 Henan,China;Quality and Safety Control Office of the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100 Henan,China)

机构地区：[1]新乡市第二人民医院肾病风湿免疫科,河南新乡453000 [2]新乡医学院第一附属医院质量与安全控制办公室,河南新乡453100

出　　处：《中国民康医学》2021年第9期111-112,115,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:比较罗沙司他与促红细胞生成素治疗维持性血液透析肾性贫血患者的效果。方法:回顾性分析2018年6月至2020年6月新乡市第二人民医院收治的64例维持性血液透析肾性贫血患者的临床资料,根据治疗方案不同分为对照组(n=32)和研究组(n=32)。对照组给予重组人促红细胞生成素治疗,研究组给予罗沙司他治疗。治疗3个月后,比较两组患者的贫血指标[红细胞计数(RBC)、血红蛋白(Hb)、血细胞比容(Hct)]水平、铁代谢指标[血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)、转铁蛋白(TRF)]水平及不良反应发生率。结果:治疗后,研究组Hb、Hct、RBC、SF、TSAT、TRF水平均高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为9.38%,低于对照组的31.25%,差异有统计学意义(P<0.05)。结论:罗沙司他治疗维持性血液透析肾性贫血患者能改善血常规和铁代谢指标水平,效果优于重组人促红细胞生成素,且安全性较好。Objective:To compare effects of Roxadustat and erythropoietin in treatment of renal anemia of patients undergoing maintenance hemodialysis.Methods:64 renal anemia patients undergoing maintenance hemodialysis admitted to the Second People’s Hospital of Xinxiang City from June 2018 to June 2020 were retrospectively analyzed.According to different treatment options,they were divided into control group(n=32)and study group(n=32).The control group was treated with recombinant human erythropoietin,while the study group was treated with Roxadustat.After 3 months of treatment,the anemia indicator levels[red blood cell count(RBC),hemoglobin(Hb),hematocrit(Hct)],iron metabolism indicator levels[serum ferritin(SF),transferrin saturation(TSAT),transferrin(TRF)]and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the levels of Hb,Hct,RBC,SF,TSAT,and TRF in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the study group was 9.38%,which was lower than 31.25%in the control group,and the difference was statistically significant(P<0.05).Conclusions:Roxadustat in the treatment of renal anemia of patients undergoing maintenance hemodialysis can improve the blood routine and iron metabolism indexes with good safety.Moreover,it is superior to recombinant human erythropoietin.

关 键 词：罗沙司他 促红细胞生成素 维持性血液透析 肾性贫血 

分 类 号：R692.5[医药卫生—泌尿科学]